Acute myeloid leukemia: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• FLT3 36
• TP53 9
• NPM1 27
• IDH 29
• KMT2A 20
• RUNX1 2
• CD123 19
• BCL-2 10
• ABL1 2
• CD33 17
• PI3K 3
• mTOR 0
• KIT 3
• JAK 1
• CD19 8
• MAPK 0
• STAT3 0
• ERK 0
• AKT 0
• CD38 6
• HDAC 2
• MYC 1
• NRF2 0
• PD-1 4
• PPAR 0
• CXCR4 0
• BRD4 0
• PD-L1 0
• RAS 0
• STING 1
• HIF-1 0
• TIM-3 0
• METTL3 0
• CD47 1
• CTNNB1 0
• JNK 0
• KRAS 0
• MEK 0
• PARP 3
• EZH2 0
• IL-6 2
• BRAF 0
• EGFR 0
• FTO 0
• HSP90 0
• PDGFR 0
• PTEN 0
• CDK4/6 0
• FGFR 2
• GPX4 0
• HMGB1 0
• NLRP3 0
• NRAS 0
• SHP2 0
• AMPK 0
• CD20 1
• IL-15 1
• MDM2 0
• PINK1 0
• PKM2 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 47+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies

  NCT06508489· Sanofi· Updated 19 Oct 2026

  “Early discontinuation based on strategic sponsor decision not driven by any safety concerns”Registry text, quoted unchanged. Source

• Terminated

  Lentivirally Redirected CD123 Autologous T Cells in AML

  NCT03766126· University of Pennsylvania· Updated 10 Jul 2026

  “Administrative reasons.”Registry text, quoted unchanged. Source

• Terminated

  Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML

  NCT05716009· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Updated 25 Jun 2026

  “Upon analysis of the first 7 participants accrued, it was determined that this combination treatment is not efficacious as treatment for patients with relapsed or refractory AML”Registry text, quoted unchanged. Source

• Terminated

  CD123 Redirected T Cells for AML in Pediatric Subjects

  NCT04678336· University of Pennsylvania· Updated 15 Oct 2025

  “Administrative reasons”Registry text, quoted unchanged. Source

• Terminated

  Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia

  NCT04342962· Gruppo Italiano Malattie EMatologiche dell'Adulto· Updated 30 Jan 2025

  “poor enrollment”Registry text, quoted unchanged. Source

• Withdrawn

  Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies

  NCT05513612· Shanghai Pudong Hospital· Updated 1 Mar 2023

  “The study is not initiated and we want it to be withdrawn.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies

  NCT06508489· Sanofi· Source

• CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

  NCT04318678· St. Jude Children's Research Hospital· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 39
• Mendelian Randomization Analysis 3
• CRISPR-Cas Systems 17
• Gene Expression Profiling 85
• Sequence Analysis, RNA 6
• Whole Genome Sequencing 7
• Exome Sequencing 1
• Proteomics 28
• Metabolomics 10
• Mass Spectrometry 3
• Flow Cytometry 87
• Immunohistochemistry 14
• Liquid Biopsy 1
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 159
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 11
• Machine Learning 33
• Deep Learning 12
• Cohort Studies 30
• Genome-Wide Association Study 3

• Immunophenotyping of Acute Myeloid Leukemia.

  Methods Mol Biol, Jan 2027

• Measurable Residual Disease.

  Methods Mol Biol, Jan 2027

• ADGRE2: A Promising Immunotherapeutic Target in Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia.

  Cancer Med, Nov 2026

• Minor Myeloid Leukemic Populations in Pediatric Acute Lymphoblastic Leukemia: A Potentially Underrecognized Mixed-Phenotype Tumor?

  Int J Mol Sci, Oct 2026

• Integrating immunophenotyping and morphology in the diagnosis of acute leukemia at the National Oncology Center, Sana'a, Yemen.

  Libyan J Med, Sept 2026

• Flow Cytometric Detection of Intracellular Proteins in K562 Human Erythroleukemia Cells Using Unconjugated Primary Antibodies.

  J Vis Exp, Sept 2026

• Pilot study on RECAF (Receptor for Alpha-Fetoprotein) expression in pediatric acute leukemia: insights from flow cytometry analysis.

  J Egypt Natl Canc Inst, Sept 2026

• Ficoll-based isolation biases the profiling of immune cells and leukemic blasts in AML samples.

  Front Immunol, Aug 2026

• Flow cytometric detection of isolated central nervous system relapse in acute myeloid leukemia under FLT3-targeted therapy.

  J Hematop, Aug 2026

• Acute myeloid leukemia with unusual mature lymphoid-like morphology in a subset of blasts.

  J Hematop, Aug 2026

See which targets of this disease your abstract mentions, and go to the people working on them.